KRAS and cancer: In this study, we uncovered that AXL/eIF4E-regulated UPR signaling network, with HSP90 at the helm of the regulatory hierarchy, is an acquired dependency of and confers a selective vulnerability in KRAS-mutant lung cancer cells resistant to chemo and anti-MEK cancer drugs.